Company / Return on Equity (ROE)
4D Molecular Therapeutics, Inc. Return on Equity (ROE) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-31.5%
FY2025
5-year range
-46.5% / -22.1%
FY2021-FY2025
Trend
+3.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
4D Molecular Therapeutics, Inc. reports negative total equity of -31.5% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-31.5% in FY2025 with a 3-year CAGR of -9.2%.
Improved from -46.5% to -31.5% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -9.2pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 3.8% year-over-year.
- Peak return on equity (roe) was recorded in FY2021.
- Lowest return on equity (roe) in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -31.5% | +3.8% |
| FY2024 | -32.8% | +29.5% |
| FY2023 | -46.5% | -107.9% |
| FY2022 | -22.4% | -1.1% |
| FY2021 | -22.1% | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026